57277-47-1

Basic information

• Product Name: N-ADAMANTAN-1-YL-3-AMINO-BENZAMIDE
• Synonyms: N-ADAMANTAN-1-YL-3-AMINO-BENZAMIDE;TIMTEC-BB SBB007496;ASINEX-REAG BAS 13091282;N-1-adamantyl-3-aminobenzamide;benzamide, 3-amino-N-tricyclo[3.3.1.1~3,7~]dec-1-yl-;BAS 13091282;Oprea1_257552;SBB007496
• CAS NO: 57277-47-1
• Molecular Formula: C₁₇H₂₂N₂O
• Molecular Weight: 270.37
• Mol File: 57277-47-1.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-ADAMANTAN-1-YL-3-AMINO-BENZAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N-ADAMANTAN-1-YL-3-AMINO-BENZAMIDE(57277-47-1)
• EPA Substance Registry System: N-ADAMANTAN-1-YL-3-AMINO-BENZAMIDE(57277-47-1)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 57277-47-1(Hazardous Substances Data)

Usage

Uses

N-Adamantan-1-yl-3-amino-benzamide can be prepared to use as anti-tumor agents.

Upstream product

• 57277-46-0 3-nitro-N-tricyclo[3.3.1.1/3,7/]dec-1-ylbenzamide 
• 121-90-4 m-nitrobenzoic acid chloride 
• 121-92-6 3-nitrobenzoic acid 

Relevant articles and documents

Adamantyl quinazoline compound, composition and application of adamantyl quinazoline compound and composition

The invention discloses an adamantyl quinazoline compound, a composition and application of the adamantyl quinazoline compound and the composition. The compound shown in a formula (I) and all possible isomers or pharmaceutically acceptable salts or hydrates or compositions are used to treat diseases caused by EGFR (Epidermal Growth Factor Receptor) tyrosine kinase, and are particularly used to treat non-small cell lung cancer, small cell lung cancer, squamous-cell carcinoma, breast cancer and gastric carcinoma.

Synthesis and in vitro virucidal properties of recent 1 substituted adamantan derivatives

-